牛牛AI助理已提取核心訊息
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of $1,428,793.11. Following the sale, Wagner's direct holdings in the company amount to 53,583 shares. The sale was conducted to cover the exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of $1,428,793.11. Following the sale, Wagner's direct holdings in the company amount to 53,583 shares. The sale was conducted to cover the exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席財務官小查爾斯·瓦格納於2024年2月23日完成了3,309股普通股的出售。該交易以每股431.79美元的價格進行，總價值爲1,428,793.11美元。出售後，瓦格納在該公司的直接持股量爲53,583股。如交易代碼 “F” 所示，此次出售是爲了通過交付或預扣證券來彌補行使價或納稅義務。
Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席財務官小查爾斯·瓦格納於2024年2月23日完成了3,309股普通股的出售。該交易以每股431.79美元的價格進行，總價值爲1,428,793.11美元。出售後，瓦格納在該公司的直接持股量爲53,583股。如交易代碼 “F” 所示，此次出售是爲了通過交付或預扣證券來彌補行使價或納稅義務。
有用
沒用